BlossomHill Therapeutics
BLSM
16.61
-0.68
-3.93%
BlossomHill Therapeutics
US · BLSM
#3711 by market cap
Listed 2026
16.61
-0.68
-3.93%
Live - 5344 symbols - heartbeat 289s ago
· 2026-10-08 04:52
Pre-market
16.34
-1.63%
After-hours
16.06
-3.31%
- Market cap
- 527.95M
- P/E (TTM)i
- -6.80
- P/Bi
- -3.02
- EPSi
- -3.69
- Div yieldi
- 0.00%
- 52W posi
- 11%
Reader sentiment
Are you bullish or bearish on BLSM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 11 in the most recent period (2026/Q3).
- Total institutional ownership rose 42.2 percentage points.
Institutional ownership
- Held by institutions
- 42.20% +42.20pp
- Institutions
- 11 +11
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund21.34%
Hedge Fund11.37%
Individual/Insider7.89%
Private Company5.39%
Mutual Fund4.09%
Other49.92%
Top holders as of 2026-08-10
Cormorant Asset Management, LP
11.37% · 3.61M sh
OrbiMed Advisors LLC
8.54% · 2.71M sh
Perceptive Advisors LLC
5.69% · 1.81M sh
The Li and Cui Family Trust
5.39% · 1.71M sh
Vivo Capital, LLC
5.29% · 1.68M sh
Janus Henderson Group plc
3.57% · 1.13M sh
Jingrong Cui
3.36% · 1.07M sh
Jingrong Jean Cui
3.36% · 1.07M sh
Brahma Capital
1.82% · 578.52K sh
Vincent Liptak
0.42% · 134.10K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
34 filings tracked · 19 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| Cormorant Asset Management, LP | -- | 11.37% |
| Jingrong Cui | -- | 3.36% |
| Vincent Liptak | General Counsel & Executive VP | 0.42% |
| Yishan Li | Co-Founder & Executive Chairperson | 0.39% |
| Sheila Gujrathi | Lead Independent Director | 0.28% |
| Geoff Oxnard | Chief Medical Officer & Executive VP | 0.06% |
| John Schmid | Independent Director | 0.02% |
| Jason Keyes | Chief Financial Officer | 0.00% |
| OrbiMed Advisors LLC | -- | -- |
| Carl Gordon | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-09 | OrbiMed Advisors LLC | -- | Open Market Acquisition | +625,000 | $16.00 |
| 2026-08-09 | OrbiMed Advisors LLC | -- | Derivative Exercise and Retained | +2,089,279 | -- |
| 2026-08-09 | John Schmid | Independent Director | Open Market Acquisition | +6,000 | $16.00 |
| 2026-08-09 | Yishan Li | Co-Founder & Executive Chairperson | Derivative Exercise and Retained | +124,779 | -- |
| 2026-08-09 | Brahma Capital | -- | Derivative Exercise and Retained | +578,524 | -- |
| 2026-08-09 | Cormorant Asset Management, LP | -- | Open Market Acquisition | +312,500 | $16.00 |
| 2026-08-09 | Cormorant Asset Management, LP | -- | Derivative Exercise and Retained | +3,301,534 | -- |
| 2026-08-09 | Jason Keyes | Chief Financial Officer | Open Market Acquisition | +700 | $16.00 |
| 2026-08-09 | Vincent Liptak | General Counsel & Executive VP | Open Market Acquisition | +4,700 | $15.80–16.00 |
| 2026-08-09 | Vincent Liptak | General Counsel & Executive VP | Derivative Exercise and Retained | +22,687 | -- |
| 2026-08-09 | The Li and Cui Family Trust | -- | Derivative Exercise and Retained | +1,714,117 | -- |
| 2026-08-05 | Carl Gordon | Independent Director | Other Derivative Acquisition | +23,904 | $16.00 |
| 2026-08-05 | John Schmid | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Yishan Li | Co-Founder & Executive Chairperson | Other Derivative Acquisition | +112,701 | $16.00 |
| 2026-08-05 | Yishan Li | Co-Founder & Executive Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Sheila Gujrathi | Lead Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Cormorant Asset Management, LP | -- | Other Derivative Acquisition | +23,904 | $16.00 |
| 2026-08-05 | Cormorant Asset Management, LP | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Sundeep Agrawal | Independent Director | Other Derivative Acquisition | +23,904 | $16.00 |
| 2026-08-05 | Sundeep Agrawal | Independent Director | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 04:52:37 · For reference only, not investment advice and not tailored to your situation.